Received Apr 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
HCP called to report a female who received their first dose of GARDASIL 9 in August of 2024 at the age of 17 has not received any subsequent doses since. No symptoms reported. Caller did not have any other information to provide at the time of the; No additional adverse event reported; This spontaneous report was received from a pharmacist and refers to a 17-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unspecified date in August 2024, the patient was vaccinated with first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), 0.5 mL (.5 ml), (lot # and expiration date were not reported) as prophylaxis, and had not received any subsequent doses since (inappropriate schedule of product administration). No additional adverse event.